Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 5Recurrence 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Waldenstrom Macroglobulinemia 2Lymphoma, Mantle-Cell 2Lymphoma 2Leukemia 2B-cell Malignancies 2Lymphoma, B-Cell 1

Interventions

zanubrutinib 2tirabrutinib 1obinutuzumab 1idelalisib 1Voriconazole 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × B-cell Malignancies × zanubrutinib × Clear all
NCT04551963 2024-10-26

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

BeiGene

Phase 1 Completed
26 enrolled 20 charts
Lymphoid

B-cell Malignancies

NCT02343120 2022-04-28

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

BeiGene

Phase 1/2 Completed
385 enrolled 29 charts 2 FDA
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡